ArriVent BioPharma Shares Rise 9.3% on Initial Cancer Trial Data
Shares gained 9.3% to $22.95 in premarket trading after ArriVent announced positive initial Phase 1 data for a gastrointestinal cancer treatment. The body is truncated after “The drug con”.
By Kelly CloonanShares of ArriVent BioPharma rose after the company announced positive initial data from a Phase 1 trial of treatment for gastrointestinal cancers.The stock gained 9.3% to $22.95 in premarket trading Monday. Shares were up 4.4% year to date at market close.ArriVent said the drug con…